The Biosimilar Hormones Market is projected to grow to $18.12 billion by 2030, with a CAGR of 23.9%.

News originally published by

EIN Presswire

Biosimilar Hormones

Biosimilar Hormones

The Business Research Company

The Business Research Company

The Business Research Company’s Biosimilar Hormones Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, November 20, 2026 /EINPresswire.com/ -- The biosimilar hormones market has been expanding rapidly, reflecting a growing shift toward more affordable and accessible hormone therapies. This sector is witnessing impressive growth fueled by various health trends and evolving healthcare infrastructure worldwide. Let’s delve into the current market size, key growth drivers, prominent regional players, and future outlook shaping this industry.

Robust Growth Forecast for the Biosimilar Hormones Market
The biosimilar hormones market is set for significant expansion, increasing from $6.22 billion in 2025 to $7.68 billion in 2026 at a striking compound annual growth rate (CAGR) of 23.5%. This impressive rise during the historic period has been driven by factors such as the growing incidence of diabetes and hormonal disorders, the high expense of branded hormone treatments, an aging global population, heightened awareness around hormone replacement therapies, and the widening reach of hospital and retail pharmacy networks.

Download a free sample of the biosimilar hormones market report:
https://thebusinessresearchcompany.com/sample_request?id=38000654&type=smp&name=Biosimilar%20Hormones%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Looking ahead, the market is projected to surge even further, reaching $18.12 billion by 2030 with a CAGR of 23.9%. This anticipated growth is supported by the expiration of patents on major biologic hormones, stronger regulatory backing for biosimilars, increasing demand for cost-effective endocrine therapies, the expansion of online pharmacy channels, and greater investment in biosimilar research and development. Key trends shaping the future include wider adoption of biosimilar hormones as economical alternatives, rising demand specifically for insulin and growth hormone biosimilars, growing physician acceptance, use in managing chronic and lifestyle diseases, and streamlined regulatory approval processes.

Understanding Biosimilar Hormones and Their Role
Biosimilar hormones are products that contain hormones chemically identical to those naturally produced by the human body. These bioidentical drugs may closely resemble conventional hormone therapies and are designed to treat individuals experiencing hormone imbalances or deficiencies. Their role is critically important in restoring hormonal equilibrium and managing related health conditions.

View the full biosimilar hormones market report:
https://thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR

Healthcare Spending as a Major Growth Catalyst
One of the primary factors propelling the biosimilar hormones market is the steady rise in healthcare expenditure worldwide. Healthcare spending encompasses all financial resources devoted to preventing, diagnosing, and treating illnesses. Advances in medical technology often come with higher costs, raising overall healthcare budgets. However, this increased expenditure also encourages greater adoption of biosimilar hormones, which offer cost-effective treatment options and improve patient access across various healthcare systems. For example, in December 2024, the Centers for Medicare & Medicaid Services reported that U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. This trend underscores how escalating healthcare costs are simultaneously driving demand for affordable hormone therapies like biosimilars.

The Diabetes Epidemic as a Key Market Driver
The rising prevalence of diabetes plays a significant role in boosting the biosimilar hormones market. Diabetes is a chronic condition affecting the body's ability to regulate blood sugar and convert food into energy effectively. Biosimilar hormones, particularly insulin, provide safe and efficient alternatives for diabetes management, potentially lowering treatment costs and increasing accessibility for patients. Biosimilar growth hormones also aid in improving blood sugar control among adults with both type 1 and type 2 diabetes. Supporting this, in June 2023, the International Diabetes Federation, a Germany-based association representing over 240 national diabetes organizations, highlighted a sharp increase in diabetes cases worldwide, forecasting that 783 million adults aged 20 to 79 will have diabetes by 2045. This trend clearly positions diabetes as a powerful driver for biosimilar hormone demand moving forward.

North America’s Dominance in the Biosimilar Hormones Market
In 2025, North America held the largest share of the biosimilar hormones market. The market report also provides detailed insights into other key regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, offering a comprehensive global perspective on market distribution and growth opportunities.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The German Business Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.